Discovery of RG7834:
The First-in-Class Selective
and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor
with Novel Mechanism of Action
posted on 2018-10-04, 00:00authored byXingchun Han, Chengang Zhou, Min Jiang, Yongguang Wang, Jianhua Wang, Zhanling Cheng, Min Wang, Yongqiang Liu, Chungen Liang, Jianping Wang, Zhanguo Wang, Robert Weikert, Wenzhe Lv, Jianxun Xie, Xin Yu, Xue Zhou, Souphalone Luangsay, Hong C. Shen, Alexander V. Mayweg, Hassan Javanbakht, Song Yang
Chronic
hepatitis B virus (HBV) infection is a serious public health
burden, and current therapies cannot achieve satisfactory cure rate.
There are high unmet medical needs of novel therapeutic agents with
differentiated mechanism of action (MOA) from the current standard
of care. RG7834, a compound from the dihydroquinolizinone (DHQ) chemical
series, is a first-in-class highly selective and orally bioavailable
HBV inhibitor which can reduce both viral antigens and viral DNA with
a novel mechanism of action. Here we report the discovery of RG7834
from a phenotypic screening and the structure–activity relationship
(SAR) of the DHQ chemical series. RG7834 can selectively inhibit HBV
but not other DNA or RNA viruses in a virus panel screening. Both
in vitro and in vivo profiles of RG7834 are described herein, and
the data support further development of this compound as a chronic
HBV therapy.